Register
Login:
Share:
Email Facebook Twitter

Share Views: The Cyber Security opportunity - What you need to know. Watch here

Share Views: The Cyber Security opportunity.
What you need to know.


Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 36.00Bid: 36.00Ask: 37.50Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 1.50Spread as %: 4.17%Open: 36.50High: 36.50Low: 35.00Yesterday’s Close: 36.00

Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
36.00

Share Price SpacerBid
36.00

Share Price SpacerAsk
37.50

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
104,823

Share Price SpacerOpen
36.50

Share Price SpacerHigh
36.50

Share Price SpacerLow
35.00

Share Price SpacerClose
36.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 121.78m £43.84m 10,000

52 Week High 48.25 52 Week High Date 2-JUN-2016
52 Week Low 19.75 52 Week Low Date 2-DEC-2015

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
17 77,566 27,257 -8.182 -4.40 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

26-Aug-16
16:35:14
36.00
5,500
Sell* 
36.00
37.50
1,980
UT 
Trade Type:
Uncrossing Trade

26-Aug-16
15:40:14
36.375
5,748
Sell* 
36.00
37.50
2,091
Trade Type:
Ordinary

26-Aug-16
15:30:43
36.375
2,287
Sell* 
36.00
37.50
831.90
Trade Type:
Ordinary




View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
30-Apr-15Notification of Holding
Trade Notifier Information for Immupharma
Stephane Robert George Mery held the position of Non-Executive Director at Immupharma at the time of this trade.
 Stephane Robert George Mery
002259
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
View more Immupharma directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Sat 10:48boomorbustMcowboy36.00No Opinion
Thanks - some useful information there
Sat 10:27McowboyRE: Lostinfrance36.00No Opinion
also of interest are the secondary objectives of the Lupuzor phase 3 trials which include the assessment of "the effect of IPP-201101 on arthritis, as assessed by the 28-joint count examination for pain and tenderness", see section E2.2 at https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003341-25/HU
Sat 08:38McowboyRE: Lostinfrance36.00No Opinion
Sat 08:33McowboyRE: Lostinfrance36.00No Opinion
According to the EU clinical trials register https://www.clinicaltrialsregister.eu/ctr-search/search?query=ipp-20110 of the 200 patients to be recruited, 140 are to be recruited within EEA countries. From the currently available trial protocol data where the trials are listed as ongoing, 40 are to be recruited in the EEA member state France, 36 in Germany and 36 in Hungary. The EU website does not include the data yet for Poland or Italy which are also listed on the site… Read More
Fri 19:20LostinfranceRE: Lostinfrance36.00No Opinion
Yes they did and also took part of fees in shares too i think,
Yes lets hope we are in the 20% but the main thing is good results,
Fri 19:05boomorbustRE: Lostinfrance36.00No Opinion
Yes - doesn't seem too unreasonable.

It's all in the hands of the CRO, Simbec-Orion now. Simbec-Orion only formed in 2014 and is trying to build its reputation as a boutique, full service CRO. As far as I know, it has picked up two phase III trials since it was launched, one in cancer with a French pharma. and the Lupuzor trial. These trials will be high profile for Simbec. They'll want to perform as well as they possibly can and that will include meeting recruitment targets. I… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Immupharma (IMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.